Induction chemotherapy for the individualised treatment of hypopharyngeal carcinoma with cervical oesophageal invasion: a retrospective cohort study

Table 2 Results of the univariate analysis of patient prognosis

Variable	Classification	N	3-year OS (%)	5-year OS (%)	Median	HR	95% CI	P value
Sex	Male	63	23.81	7.47	24	1.142	0.4718–2.765	0.7682
Sex	Female	5	20.00	0.00	32	1.142	0.4718–2.765	0.7682
Age (years)	≤ 60	50	32.00	0.00	23.5	0.5572	0.2906–1.068	0.0782
Age (years)	> 60	18	9.14	0.00	24.5	0.5572	0.2906–1.068	0.0782
Subsite	Pyriform sinus	27	22.22	7.41	24	Ps:Pr: 1.1650 Ps:Pw: 0.8446 Pr:Pw: 0.7327	Ps:Pr: 0.6202–2.188 Ps:Pw: 0.4687–1.522 Pr:Pw: 0.3833–1.401	0.6417
	Post-cricoid region	18	22.22	5.56	26
	Posterior wall	23	26.09	8.70	19
Differentiation	High	14	21.43	7.14	27	H:M: 0.8906 H:P: 0.7915 M:P: 0.8499	H:M: 0.4698–1.688 H:P: 0.3869–1.619 M:P: 0.4690–1.540	0.7899
	Moderate	35	28.57	11.43	23
	Poor	19	15.79	5.26	23
N classification	N0	19	26.32	10.53	24	1.004	0.5760–1.749	0.9899
N classification	N1–3	49	22.45	8.16	24	1.004	0.5760–1.749	0.9899
Drinking	Yes	42	23.81	7.14	23	1.151	0.6950–1.905	0.5855
Drinking	No	26	23.08	11.54	26	1.151	0.6950–1.905	0.5855
Smoking	Yes	47	21.28	6.38	24	1.181	0.6991–1.994	0.0740
Smoking	No	21	28.57	14.29	27	1.181	0.6991–1.994	0.0740
TPF regime	Yes	35	31.43	8.57	24	0.848	0.5235–1.375	0.5021
TPF regime	No	33	24.24	6.06	23	0.848	0.5235–1.375	0.5021
Surgery	Yes	55	27.27	7.27	24	1.044	0.5766–2.055	0.8926
Surgery	No	13	30.77	7.69	22	1.044	0.5766–2.055	0.8926

CI confidence interval, H high, HR hazard ratio, M moderate, OS overall survival, P poor, Pr post-cricoid region, Ps pyriform sinus, Pw posterior wall, TPF paclitaxel + platinum + fluorouracil

ISSN: 1477-7819